REGEN-COV™ (casirivimab/imdevimab) – Emergency use authorization expansion
July 30, 2021 - Regeneron announced the emergency use authorization approval of REGEN-COV (casirivimab/imdevimab), in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:
Top